TB infection: An exploratory study of BCG protective properties and the possible role of environmental mycobacteria

Central African Journal of Medicine

Volumn 44, Issue 6, 1998, Pages 145-148

  Chihota, V N ^a   Nyazema, N Z ^a   Mashingaidze, S ^a   Mutandiro, B ^b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b Blair Research Institute   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; BACTERIAL FLORA; BACTERIUM ISOLATION; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM SCROFULACEUM; TUBERCULIN TEST; TUBERCULOSIS; ZIMBABWE;

BCG VACCINE; ENVIRONMENTAL MONITORING; HUMANS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM SCROFULACEUM; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SOIL MICROBIOLOGY; TIME FACTORS; TUBERCULOSIS; URBAN HEALTH; WATER MICROBIOLOGY; ZIMBABWE;

EID: 0031790799     PISSN: 00089176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. J Am Med Assoc 1995;273(3):220-6.
2. Chihota V, Charimari LZ. Diagnosis and control of communicable disease in Zimbabwe. Paper presented at the 1997-1998 regional project on the use of advanced nuclear and biological techniques of diagnosis and control of communicable diseases in Africa. 1996,2-4.
3. Centres for Disease Control and Prevention (CDC, MMWR). The role of BCG vaccine in the prevention and control of tuberculosis in United States. MMWR. US Government Printing Office. Washington. 1996;45(4):1-18.
4. Fine PEM, Rodrigues LC. Mycobacterial disease. In: a Lancet review: Modern vaccines. Moxon ER, editor. London: Edward Arnold, 1990:67-74.
5. Colditz GA, Brewer T, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. J Am Med Assoc 1994;271:698-702.
6. Stanford JL, Grange JM. New concepts for the control of tuberculosis in the twenty first century. J Royal Coll Physicians London 1993;27(3):219-23.
7. Constock GW, Livesay VT, Woolpert SS. Evaluation of BCG among Puerto Ricans. Am J Public Health 1974;64:283-91.
8. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1333-45.
9. Fine PEM, Stem JAC, Penning Haus JM, Rees RJW. Delayed hypersensitivity mycobacteria vaccines and protective immunity. Lancet 1994;344:1245-9.
10. Von Reyn FC, Waddell RD, Eaton T, Arbert RD. Maslow NJ, Barber TW, et al. Isolation of Mycobacterium avium complex from water in United States, Finland, Zaire and Kenya. J Clin Microbiol 1993;3:3227-30.
11. Kleeberg HH, Koornhof HJ, Palmhert H, editors. Laboratory manual of tuberculosis methods. Pretoria: Health Laboratory Services, 1967:13-4.
12. Koneman EW, Allen SD, Dowell Jr VR, Janda WM, Sommers HM, et al. Colour atlas and textbook for diagnostic microbiology. 3rd ed. Biello LA, Robinson SJ, Ewan H, editors. Philadelphia: Lippincott Company: 1988;535-72.
13. Brewer TF, Colditz GA. Relationship between Bacilli Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995;20:1235.
14. Centres for Disease Control and Prevention (CDC, MMWR). The role of BCG vaccine in the prevention and control of tuberculosis in the United States. MMWR 1996;45(4):1-18.
15. Stanford JL, Shield MJ, Rook GAW. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 1981;62:55-62.
16. Palmer CE, Long MW, Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1996;94:553-68.